Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group lowered its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 38.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 417,253 shares of the company's stock after selling 260,199 shares during the period. Schroder Investment Management Group owned about 0.53% of Travere Therapeutics worth $7,227,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Rhumbline Advisers increased its stake in Travere Therapeutics by 2.2% during the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company's stock worth $2,112,000 after buying an additional 2,640 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Travere Therapeutics by 13.5% in the fourth quarter. Arizona State Retirement System now owns 22,396 shares of the company's stock worth $390,000 after acquiring an additional 2,666 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Travere Therapeutics during the fourth quarter worth approximately $53,000. Diversified Trust Co raised its stake in Travere Therapeutics by 27.5% in the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company's stock valued at $256,000 after purchasing an additional 3,169 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Travere Therapeutics by 20.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company's stock valued at $279,000 after purchasing an additional 3,458 shares during the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TVTX. Evercore ISI upped their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. increased their price objective on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. HC Wainwright boosted their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, January 15th. Finally, Citigroup increased their price target on Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a report on Monday, February 24th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Travere Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $31.46.

Travere Therapeutics Trading Up 1.4 %

Shares of Travere Therapeutics stock traded up $0.20 during trading hours on Wednesday, hitting $14.35. The company's stock had a trading volume of 3,375,763 shares, compared to its average volume of 1,524,920. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -3.50 and a beta of 0.84. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29. The firm has a fifty day moving average of $19.86 and a 200-day moving average of $18.57.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. Research analysts forecast that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 3,348 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $20.12, for a total value of $67,361.76. Following the sale, the chief accounting officer now owns 63,654 shares of the company's stock, valued at $1,280,718.48. The trade was a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP William E. Rote sold 2,437 shares of the company's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $47,424.02. Following the transaction, the senior vice president now owns 83,170 shares in the company, valued at $1,618,488.20. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 188,829 shares of company stock worth $4,146,997. 4.06% of the stock is currently owned by insiders.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.